Ledda A, Bottari A, Luzzi R, Belcaro G, Hu S, Dugall M, Hosoi M, Ippolito E, Corsi M, Gizzi G, Morazzoni P, Riva A, Giacomelli L, Togni S
IRVINE3 Vascular/Circulation Labs, Deparment of Biomedical Sciences, Chieti-Pescara University, Pescara, Italy, and Samaritans, Spoltore, PE, Italy.
Eur Rev Med Pharmacol Sci. 2015 Jan;19(1):77-80.
Cranberry extracts have been tested as a nutritional supplementation in the prevention of recurrent lower-urinary tract infections (R-UTIs), with mixed results. This pilot, registry study evaluates the prophylactic effects of oral supplementation with a new well-standardized cranberry extract in patients with R-UTI, over a 2-month follow-up.
All subjects were suggested to take one capsule containing a cranberry extract (Anthocran™) for 60 days and were also given lifestyle advice. Clinical outcomes were compared between patients on cranberry extracts and those who don't take this supplementation.
In total, 22 subjects completed the study in each of the two groups. In the cranberry group, the reduction in the frequency of UTI episodes during the study period compared with the two months before the inclusion was 73.3% (p < 0.05). This figure was 15.4% in the control group (p < 0.05; p = 0.012 vs cranberry group). Seven (31.8%) subjects in the cranberry group were symptom-free; no patient was symptom-free in the control group (p < 0.05). The mean duration of UTI episodes was 2.5 ± 1.3 days in the cranberry group, compared with 3.6 ± 1.7 days in subjects not on cranberry (p < 0.05). Three subjects (13.6%) in the cranberry group and 8 (36.3%) in the control group required medical consultation for UTI symptoms (p < 0.05). Urine evaluation was completely negative in 20/22 subjects in the Cranberry group (90.9%) and in 11 control subjects (50.0%; p < 0.005). No adverse events were observed.
These preliminary results, obtained in a field-practice setting, indicates the effectiveness and safety of a well-standardized cranberry extract in the prevention of R-UTI.
蔓越莓提取物已作为营养补充剂用于预防复发性下尿路感染（R-UTIs），但结果不一。这项初步的注册研究评估了一种新的标准化良好的蔓越莓提取物口服补充剂对R-UTI患者的预防效果，随访期为2个月。
所有受试者均被建议服用一粒含有蔓越莓提取物（Anthocran™）的胶囊，为期60天，并给予生活方式建议。对服用蔓越莓提取物的患者和未服用该补充剂的患者的临床结果进行比较。
两组各有22名受试者完成了研究。在蔓越莓组中，与纳入研究前两个月相比，研究期间UTI发作频率降低了73.3%（p<0.05）。对照组的这一数字为15.4%（p<0.05；与蔓越莓组相比p=0.012）。蔓越莓组中有7名（31.8%）受试者无症状；对照组中无患者无症状（p<0.05）。蔓越莓组UTI发作的平均持续时间为2.5±1.3天，未服用蔓越莓的受试者为3.6±1.7天（p<0.05）。蔓越莓组中有3名受试者（13.6%），对照组中有8名受试者（36.3%）因UTI症状需要就医咨询（p<0.05）。蔓越莓组22名受试者中有20名（90.9%）尿液评估完全为阴性，对照组中有11名受试者（50.0%；p<0.005）。未观察到不良事件。
在实际临床环境中获得的这些初步结果表明，一种标准化良好的蔓越莓提取物在预防R-UTI方面有效且安全。
